The results from animal studies1–3 and preliminary findings from human clinical trials (NCT031635114,5 and NCT04786262) suggest that physiological insulin replacement therapy for diabetes may be achievable by transplanting β like cells derived from human pluripotent stem cells (hPSCs). The gene discussed is INS; the disease is diabetes mellitus.